In the detection of early malignant tumors, PET-CT, which is similar in appearance to CT machine, has much more insight than CT, but it costs at least 7000 yuan to do a PET-CT examination at present. At present, international teams, technology and capital in this field are gathering in Shanghai, which is good news for both industrial upgrading and patients. Local companies break through the high-end "we hope to reduce the inspection fee of PET-CT by 2/3 through independent research and development and localization." Zhang Qiang, president of Shanghai Lianying Medical Technology Co., Ltd., told reporters. Founded in 2011, Lianfeng has developed its own PET-CT, and has cooperated with hospitals in Shanghai to carry out clinical demonstration applications. This is the first PET-CT independently developed in China. Previously, the market was monopolized by two or three multinational companies, and the price of a single device was as high as 20 million yuan. Medical equipment is an area of high technology added value in manufacturing industry, but more than 80% of the high-end market is occupied by foreign-funded enterprises. At present, Shanghai regards biomedicine as a strategic emerging industry focusing on development. With the promotion of the Municipal Science and Technology Commission, it will further focus on high-end medical devices, research and development and industrialization in the future. In the Chinese industry, Lianfu has absolute strength. Its R&D team is equal to the sum of four or five similar leading enterprises in China. In the past two years, it has applied for hundreds of patents, launched in the entire high-end medical imaging product line, digital X-ray machine, CT, magnetic resonance and other products have been approved by the State Drug Administration. The internationalization background is the key factor for the rise of the joint film. It has gathered a large number of returnees from around the world who have great influence in medical imaging, many of whom have been senior executives of multinational corporations. Talents are the most important factor in the development of medical device industry. Only with a complete world-class team, can we truly enter the traditional territory of multinational giants. The company reflects Shanghai's potential in integrating international resources and developing high-end medical device industry. Shanghai Attracts Entrepreneurial Talents
Wang Yunlong, deputy secretary-general of Shanghai Medical Devices Industry Association, said that Chinese people have made a lot of contributions in the field of medical devices. As governments and funds around the world pay more attention to the high-end medical device industry, their desire to return home is growing. Wang Zhengbin of Deno Capital said that the composition of medical expenditure in developed countries is 1:1 for medical devices and drugs and 1:4 for China, which has great potential. And unlike new drug research and development, many innovations in medical devices come from small companies, which is different from the situation in which innovative drugs are completely controlled by giants, and later generations can make a difference. The enthusiasm for capital coincides with the government's ideas. Shanghai Jiading Industrial Park has just entered a new batch of biomedical manufacturing bases in Shanghai, focusing on the development of independent high-end medical equipment industry. Regarding the output value of unit land, the medical equipment may be the highest in the manufacturing industry, which is in line with Shanghai's industrial development strategy, said General Manager Lei Wenlong. On the other hand, Shanghai's talent team, medical level, industry support and financial environment are very suitable for the entrepreneurs of high-end medical devices. Under the favorable circumstances, some leaders who can not fulfill their ambitions overseas choose to return home. Shanghai Sanyou Medical Devices Co., Ltd. developed the highest level of spinal implants representing orthopaedic devices. Liu Mingyan, chairman of the company, had previously been the chief scientist of a leading global company. He said that China has the best orthopaedic surgeons in the world, but he has never been able to convince the CEO to cooperate with Chinese doctors to develop devices suitable for Chinese patients. Zhou Daixing, the founder of Berry and Kang, was the Asia-Pacific head of a top DNA sequencing equipment manufacturer in the United States. Five years ago, he developed a technology to screen for genetic diseases in fetuses, but American companies were reluctant to support it. At present, it is one of the 34 companies in the world that can provide similar services, and raised hundreds of millions of yuan again last year. Zhang Qiang also said that in the original enterprise, they saw that there were many areas for improvement in traditional equipment, but they had no chance to achieve it until the founding of the film. At present, Sanyou, Berry and Kang have all been stationed in Jiading, just like the joint film. Overseas Distribution of Capital Technology
In Shanghai medical equipment industry, the international resources being imported are far more than talents. Over the past year, Shanghai medical companies have led two cross-border mergers and acquisitions that have received widespread attention: in December, $290 million was spent by "minimally invasive medicine" to acquire the joint reconstruction business of American Reiter Orthopaedics Company; in May, Fuxing Pharmaceutical acquired 95.7% of Alam, an Israeli laser diagnostic and therapeutic equipment company, for $220 million. These two mergers and acquisitions fully reflect the determination of local companies with sufficient strength to invest overseas in the future. Mature businesses are expensive, and relatively inexpensive overseas start-ups have become the target of Chinese capital. At present, Denault Capital has five medical device projects to be industrialized in Shanghai. Four of them are early projects discovered and invested overseas after raising US dollar funds. Depending on them, Denault has established a high-end medical device incubator in Shanghai and will continue to look for good projects globally in the future. Syndicate also makes technical layout overseas. After defeating several multinational giants, it acquired six patents from a top team in the United States, significantly improving the resolution of PET-CT to tumors. Zhang Qiang said that Chinese medical device companies have been making small and fast money in low-end areas for a long time. Some people have said that it is impossible to challenge the giants, but now it is time to become "Huawei in the medical industry".

Next:Nothing